Nuvilex Announces Name Change to PharmaCyte Biotech
SILVER SPRING, MD., Jan. 7, 2015 — Nuvilex, Inc. (NVLX) today announced that the Company has changed its name to PharmaCyte Biotech, Inc. Shares in PharmaCyte Biotech will trade under the new ticker symbol “PHCB” on the OTCQB electronic platform. The new symbol is expected to become effective at the open of the market on January 8, 2014. The name change ...
Read More →
7
JAN
Share
FDA Grants Orphan Drug Designation to Nuvilex, Inc. for Pancreatic Cancer Treatment
SILVER SPRING, Md., Dec. 22, 2014 — Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Nuvilex orphan drug designation for its pancreatic cancer treatment. Nuvilex’s pancreatic cancer treatment combines Nuvilex’s patented and proprietary cellulose-based encapsulation technology, known as Cell-in-a-Box(R), with the cancer prodrug ifosfamide and encapsulated live cells that convert the prodrug into its cancer-killing form. These capsules are ...
Read More →
22
DEC
Share
Nuvilex Begins Preclinical Studies at Translational Drug Development
SILVER SPRING, Md., Aug. 20, 2014 — Nuvilex, Inc. (NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that studies are underway at Translational Drug Development’s (TD2) facilities in Scottsdale, Arizona, to determine if Nuvilex’s unique cancer treatment can slow the accumulation of fluid, known as “malignant ascites,” in the abdomen that is characteristic of the growth of many abdominal tumors.
Kenneth L. Waggoner, CEO and President ...
Read More →
20
AUG
Share